Hrt Financial LP Biocryst Pharmaceuticals Inc Transaction History

Hrt Financial LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$4.98 - $6.77 $396,975 - $539,663	79,714 Added 37.48%	292,412 $1.75 Million
Q3 2023 Nov 13, 2023	BUY	$6.71 - $7.92 $460,547 - $543,597	68,636 Added 47.64%	212,698 $1.51 Million
Q2 2023 Aug 11, 2023	BUY	$6.96 - $8.81 $569,599 - $721,001	81,839 Added 131.53%	144,062 $1.01 Million
Q1 2023 May 12, 2023	BUY	$7.94 - $11.84 $494,050 - $736,720	62,223 New	62,223 $518,000
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $256,834 - $352,522	23,803 New	23,803 $299,000
Q4 2021 Feb 14, 2022	SELL	$11.18 - $15.46 $1.41 Million - $1.95 Million	-126,125 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$14.21 - $17.65 $107,640 - $133,698	7,575 Added 6.39%	126,125 $1.81 Million
Q2 2021 Aug 16, 2021	BUY	$9.5 - $17.24 $747,840 - $1.36 Million	78,720 Added 197.64%	118,550 $1.87 Million
Q1 2021 May 17, 2021	SELL	$7.37 - $13.61 $1.93 Million - $3.56 Million	-261,852 Reduced 86.8%	39,830 $405,000
Q4 2020 Feb 16, 2021	BUY	$3.37 - $8.61 $1.02 Million - $2.6 Million	301,682 New	301,682 $2.25 Million
Q4 2019 Feb 14, 2020	SELL	$1.59 - $3.45 $123,104 - $267,112	-77,424 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$2.5 - $3.73 $193,560 - $288,791	77,424 New	77,424 $221,000

257

173M

397K

444K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.57B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.